301333 R&G PharmaStudies
- 39.09
- -0.64-1.61%
R&G PharmaStudies News
R&G PharmaStudies: Announcement on the completion of the election of the board of directors and the board of supervisors and the appointment of senior management
R&G PharmaStudies: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
R&G PharmaStudies: Legal Opinion of Beijing Junhe Law Firm on the 2023 Annual General Meeting of Shareholders of Norske (Beijing) Pharmaceutical Technology Co., Ltd.
R&G PharmaStudies: Announcement on the election of employee representative supervisors of the fourth board of supervisors
R&G PharmaStudies: Announcement on Additional Provisional Proposals for the 2023 Annual General Meeting of Shareholders and Supplementary Notice to the Shareholders' Meeting
R&G PharmaStudies: Announcement on the progress of joint investment and establishment of industrial funds and related transactions with professional institutions
R&G PharmaStudies: China International Finance Corporation's 2023 Follow-up Report on Norske (Beijing) Pharmaceutical Technology Co., Ltd.
Norsk: Rules of work for the Board of Directors Audit Committee
Norsk: Announcement on the use of some idle funds raised and own funds for cash management
Norsk: external guarantee system
Norske: Announcement on the election of the Board of Directors for a new term
Norske: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Norsk: Rules of work for the Board Nomination Committee
Norsk: Announcement on the revision of the corporate governance system
Norske: Announcement on the election of the Board of Supervisors for a new term
Norske: Independent Directors' Annual Report Work System
Norsk: 2023 Annual Financial Report
Norsk: Board of Directors Rules of Procedure
Norsk: Rules of work of the Board's Remuneration and Assessment Committee
Norske: Notice on amending the company's articles of association and registration of industrial and commercial changes
Analysis
Price Target
No Data
